Patient-Derived Glioblastoma Organoids as Real-Time Avatars for Assessing Responses to Clinical CAR-T Cell Therapy

Investigators analyzed six sets of patient-derived glioblastoma organoids treated concurrently with the same autologous CAR-T cell products as patients in our phase I study.